在老年人使用口服羟吗啡酮。

文章的细节

引用

复制到剪贴板

Guay博士

在老年人使用口服羟吗啡酮。

制药咨询。2007年5月,22 (5):417 - 30。

PubMed ID

17658959 (在PubMed

]

文摘

目的:回顾药效学、药物动力学、疗效、耐受性、剂量和作用口服羟吗啡酮速(IR)和延长释放(ER)。数据来源:MEDLINE / PUBMED搜索(1970年至2006年9月)的英语学习。得到了额外的引用书目。研究选择:所有人类的研究综述了羟吗啡酮。数据综合:口服羟吗啡酮红外/ ER平板配方批准2006年6月。羟吗啡酮,一种半合成的阿片类受体激动剂在结构上类似于hydromorphone,口服生物利用度约为10%。羟吗啡酮广泛代谢6-hydroxyoxymorphone oxymorphone-3-glucuronide和活跃。快速清关规定每四到六小时剂量(IR)和每12小时的剂量(ER)。肝损害、肾功能损害和衰老增强系统性风险。羟吗啡酮红外优于安慰剂,羟考酮红外(急性疼痛的研究)。 Oxymorphone ER was superior to placebo and equivalent to oxycodone CR and morphine CR (one acute and five chronic pain studies). Oxymorphone exhibits the expected opioid side effects, being comparable to oxycodone and morphine in clinical trials. Coadministration with ethanol causes "dose-dumping" (ER) and increases intersubject variability in drug absorption. Oxymorphone IR is indicated for the relief of moderate-to-severe pain, while oxymorphone ER is indicated for persistent pain. Initial doses (opioid-naive) are 10 mg to 20 mg every 4 to 6 hours (IR) and 5 mg every 12 hours (ER). Dosage adjustment is recommended in mild hepatic impairment (Child-Pugh class A), renal impairment (creatinine clearance below 50 mL/min), and in the elderly. CONCLUSION: Oxymorphone is the newest oral opioid to enter a crowded marketplace now totaling 12 Schedule 2 opioids. It does not appear to have any unique assets or liabilities and should be considered as one of many oral opioids for the management of acute and persistent pain of moderate-to-severe intensity.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Hydromorphone	三角洲类型阿片受体	蛋白质	人类	是的	部分激动剂	细节